Kuhajda F P, Bohn H, Mendelsohn G
Cancer. 1984 Oct 1;54(7):1392-6. doi: 10.1002/1097-0142(19841001)54:7<1392::aid-cncr2820540727>3.0.co;2-m.
Ectopic production of placental proteins by a variety of nontrophoblastic epithelial tumors is well recognized. Pregnancy-specific beta-1 glycoprotein (SP-1), a recently described placental protein, has been detected both in the serum and tumors of patients with breast carcinoma. To assess the significance of SP-1 in breast carcinoma, we stained 139 cases of primary breast carcinoma for SP-1 using the immunoperoxidase technique. Overall, 55 (40%) of breast cancers were positive for SP-1; focal positivity was also noted in normal breast epithelium and fibrocystic disease. Both intraductal (32%) and infiltrating duct (43%) carcinomas were more often positive than either in situ (5%) or infiltrating (26%) lobular carcinomas. SP-1 positivity in tumors of infiltrating duct morphology less than 3 cm in diameter, correlated highly (P less than 0.01) with the presence of axillary lymph node metastases. The presence of SP-1 in normal breast epithelium and fibrocystic disease and the low rate of positivity in lobular carcinoma casts doubt on the usefulness of SP-1 as a tumor marker. However, these findings suggest that immunopositivity for SP-1 in small infiltrating duct carcinomas may be an indicator of poor prognosis.
多种非滋养层上皮肿瘤异位产生胎盘蛋白已得到充分认识。妊娠特异性β-1糖蛋白（SP-1）是一种最近发现的胎盘蛋白，在乳腺癌患者的血清和肿瘤中均有检测到。为评估SP-1在乳腺癌中的意义，我们采用免疫过氧化物酶技术对139例原发性乳腺癌进行SP-1染色。总体而言，55例（40%）乳腺癌SP-1呈阳性；在正常乳腺上皮和纤维囊性疾病中也观察到局灶性阳性。导管内癌（32%）和浸润性导管癌（43%）的阳性率均高于原位癌（5%）或浸润性小叶癌（26%）。直径小于3 cm的浸润性导管形态肿瘤中SP-1阳性与腋窝淋巴结转移高度相关（P<0.01）。SP-1在正常乳腺上皮和纤维囊性疾病中的存在以及小叶癌的低阳性率使人对SP-1作为肿瘤标志物的实用性产生怀疑。然而，这些发现表明，小浸润性导管癌中SP-1免疫阳性可能是预后不良的一个指标。
